162 related articles for article (PubMed ID: 25495981)
1. Pharmacophore modeling for COX-1 and -2 inhibitors with LigandScout in comparison to Discovery Studio.
Temml V; Kaserer T; Kutil Z; Landa P; Vanek T; Schuster D
Future Med Chem; 2014; 6(17):1869-81. PubMed ID: 25495981
[TBL] [Abstract][Full Text] [Related]
2. Combining ethnopharmacology and virtual screening for lead structure discovery: COX-inhibitors as application example.
Rollinger JM; Haupt S; Stuppner H; Langer T
J Chem Inf Comput Sci; 2004; 44(2):480-8. PubMed ID: 15032527
[TBL] [Abstract][Full Text] [Related]
3. Prospective performance evaluation of selected common virtual screening tools. Case study: Cyclooxygenase (COX) 1 and 2.
Kaserer T; Temml V; Kutil Z; Vanek T; Landa P; Schuster D
Eur J Med Chem; 2015; 96():445-57. PubMed ID: 25916906
[TBL] [Abstract][Full Text] [Related]
4. Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening.
Estevão MS; Carvalho LC; Freitas M; Gomes A; Viegas A; Manso J; Erhardt S; Fernandes E; Cabrita EJ; Marques MM
Eur J Med Chem; 2012 Aug; 54():823-33. PubMed ID: 22796043
[TBL] [Abstract][Full Text] [Related]
5. Using active site mapping and receptor-based pharmacophore tools: prelude to docking and de novo/fragment-based ligand design.
Tripathi A; Surface JA; Kellogg GE
Methods Mol Biol; 2011; 716():39-54. PubMed ID: 21318899
[TBL] [Abstract][Full Text] [Related]
6. Molecular Docking of Bioactive Compounds Against BRCA and COX Proteins.
Prog Drug Res; 2016; 71():181-3. PubMed ID: 26939289
[TBL] [Abstract][Full Text] [Related]
7. Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase.
Li Y; Chen SH; Ou TM; Tan JH; Li D; Gu LQ; Huang ZS
Bioorg Med Chem; 2011 Mar; 19(6):2074-83. PubMed ID: 21349729
[TBL] [Abstract][Full Text] [Related]
8. Chemical and structural diversity in cyclooxygenase protein active sites.
Huff RG; Bayram E; Tan H; Knutson ST; Knaggs MH; Richon AB; Santago P; Fetrow JS
Chem Biodivers; 2005 Nov; 2(11):1533-52. PubMed ID: 17191953
[TBL] [Abstract][Full Text] [Related]
9. Isoxazole-Based-Scaffold Inhibitors Targeting Cyclooxygenases (COXs).
Perrone MG; Vitale P; Panella A; Ferorelli S; Contino M; Lavecchia A; Scilimati A
ChemMedChem; 2016 Jun; 11(11):1172-87. PubMed ID: 27136372
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: Molecular docking study.
Abdel-Aziz AA; ElTahir KE; Asiri YA
Eur J Med Chem; 2011 May; 46(5):1648-55. PubMed ID: 21388719
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of dithiolethiones as novel cyclooxygenase inhibitors.
Zanatta SD; Manallack DT; Jarrott B; Williams SJ
Bioorg Med Chem Lett; 2009 Jan; 19(2):459-61. PubMed ID: 19056264
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study.
El-Sayed MA; Abdel-Aziz NI; Abdel-Aziz AA; El-Azab AS; Asiri YA; Eltahir KE
Bioorg Med Chem; 2011 Jun; 19(11):3416-24. PubMed ID: 21570309
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of 2-methyl-3-indolylacetic derivatives as anti-inflammatory agents that inhibit preferentially cyclooxygenase 1 without gastric damage.
Perissutti E; Fiorino F; Renner C; Severino B; Roviezzo F; Sautebin L; Rossi A; Cirino G; Santagada V; Caliendo G
J Med Chem; 2006 Dec; 49(26):7774-80. PubMed ID: 17181159
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potential and selective COX-1 inhibitory leads using pharmacophore modelling, in silico screening and in vitro evaluation.
Balaji B; Hariharan S; Shah DB; Ramanathan M
Eur J Med Chem; 2014 Oct; 86():469-80. PubMed ID: 25203777
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cyclooxygenase by blocking the reducing cosubstrate at the peroxidase site: Discovery of galangin as a novel cyclooxygenase inhibitor.
Bai HW; Yang C; Wang P; Rao S; Zhu BT
Eur J Pharmacol; 2021 May; 899():174036. PubMed ID: 33737009
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
Rao PN; Chen QH; Knaus EE
J Med Chem; 2006 Mar; 49(5):1668-83. PubMed ID: 16509583
[TBL] [Abstract][Full Text] [Related]
17. Interactions of selected indole derivatives with COX-2 and their in silico structure modifications towards the development of novel NSAIDs.
Dileep KV; Remya C; Tintu I; Sadasivan C
J Biomol Struct Dyn; 2014; 32(11):1855-63. PubMed ID: 24053423
[TBL] [Abstract][Full Text] [Related]
18. In Vitro and In Silico Evaluation of New 1,3,4-Oxadiazole Derivatives of Pyrrolo[3,4-
Peregrym K; Szczukowski Ł; Wiatrak B; Potyrak K; Czyżnikowska Ż; Świątek P
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502040
[TBL] [Abstract][Full Text] [Related]
19. The Molecular Basis for Dual Fatty Acid Amide Hydrolase (FAAH)/Cyclooxygenase (COX) Inhibition.
Palermo G; Favia AD; Convertino M; De Vivo M
ChemMedChem; 2016 Jun; 11(12):1252-8. PubMed ID: 26593700
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, molecular docking, and biological evaluation of some novel hydrazones and pyrazole derivatives as anti-inflammatory agents.
Mohammed KO; Nissan YM
Chem Biol Drug Des; 2014 Oct; 84(4):473-88. PubMed ID: 24720475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
